Physician profile
David Stephen Mclaughlin
NPI 1801921192
$1,378.04
in general payments reported to CMS, 2019-2025
18 companies · $133 in 2025
The $133 reported for 2025 was less than what a typical Reproductive Endocrinology provider received nationally (typical 2025 total: $140).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $34.85 · 2020: $142 · 2021: $314 · 2022: $315 · 2023: $177 · 2024: $262 · 2025: $133.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $573.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $572.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $535.58 | 2019-2025 | |
| Novo Nordisk INC | $103.26 | 2021-2025 | Wegovy, Saxenda |
| Aspira Women'S Health INC | $101.46 | 2022 | |
| Hologic Sales and Service, LLC | $93.43 | 2020-2024 | Myosure Tissue Removal Device |
| Astellas Pharma US INC | $91.12 | 2024-2025 | Veozah |
| Pfizer INC. | $76.00 | 2023 | |
| Axonics, INC. | $65.18 | 2024 | Axonics, Bulkamid |
| Therapeuticsmd, INC. | $63.29 | 2020-2022 | |
| Sun Pharmaceutical Industries INC. | $51.17 | 2024 | |
| Antares Pharma, INC. | $45.20 | 2022-2024 | Xyosted, Tlando, Nocdurna |
| Halozyme INC | $33.20 | 2023 | |
| Exeltis, USA INC. | $27.94 | 2021 | |
| Millicent US INC | $19.08 | 2025 | Intrarosa |
| Currax Pharmaceuticals LLC | $17.49 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $15.68 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acerus Pharmaceuticals Corporation | $13.35 | 2022 | |
| Lilly USA, LLC | $13.25 | 2022 | |
| Scynexis, INC. | $12.36 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Mclaughlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.